Recurrent glioblastoma multiformeElderly patientsRe-ResectionINTRODUCTION:Elderly patients constitute an expanding part of our society. Due to a continuously increasing life expectancy, an optimal quality of life is expected even into advanced age. Glioblastoma (GBM) is more common in older patients, but...
In this study, preoperative Sacituzumab Govitecan was determined to accumulate to considerable amounts in the intracranial tumor tissue of both brain metastasis from breast cancer and recurrent glioblastoma. There are several completed and ongoing clinical trials of ADC in brain metastasis, predominantly...
prospective window-of-opportunity trial (NCT03995706) at the University of Texas Health Science Center at San Antonio to examine the intra-tumoral concentrations and intracranial activity of SG in patients undergoing craniotomy for breast cancer with brain metastases (BCBM) or recurrent glioblastoma (...
Figure 2. Overall Survival and Subgroup Analyses for Patients with Newly Diagnosed Glioblastoma View LargeDownload A, Kaplan-Meier plot comparing overall survival for patients with newly diagnosed glioblastoma treated with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) and 1366 contempo...
Here we report a completed phase I trial evaluating IL-13Rα2-targeted CAR-T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were safety and feasibility, maximum tolerated dose/maximum feasible dose and a recommended ...
The FDA has granted breakthrough device designation to Alpha Diffusing Alpha-emitters Radiation Therapy (DaRT) for the treatment of patients with recurrent glioblastoma multiforme (GBM), according to a press release issued by Alpha Tau Medical.1 The use of Alpha DaRT involves the inse...
When compared to glioblastoma, thyroid carcinoma, renal cell carcinoma and hepatocellular carcinoma that all express PSMA in the tumour’s neovasculature and not intracellular, ligand uptake in salivary gland tumours is moderate to weak. Further research should reveal whether salivary gland cancer ...
TTFields were successfully tested in patients with newly diagnosed glioblastoma, leading to a significant prolongation of overall survival (OS) when given in combination with maintenance temozolomide [18]. The anti-mitotic effects of TTFields have been shown in multiple tumor models [17,23]. In ...
The study will include 53 patients with recurrent or progressive, MGMT unmethylated glioblastoma. The additional 10 patients were treated in the phase IB. All patients will receive a combination of bortezomib 1.3mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with ...
The rational use for autologous leukocyte (lymphocyte) infusions was based on in vitro autologous lymphocyte cytotoxicity to glioblastoma cells in the absence of serum inhibitory factors. Seven of 17 patients treated had life expectancy under 1 month; all patients had received definitive surgery,...